SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published articles

17 Jan 2013 07:00

RNS Number : 7246V
Tristel PLC
17 January 2013
 



Tristel plc

("Tristel")

 

Peer-reviewed published articles supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of two articles in peer-reviewed journals that describe the benefits of Tristel products.

 

The first is titled "Guidelines for Reprocessing Non-lumened Heat-Sensitive Ear/Nose/Throat Endoscopes" and has been published in The Laryngoscope, the journal of The American Laryngological, Rhinological and Otological Society (Laryngoscope , 122:1708-1718, 2012). The article proposes the standardisation of disinfection procedures for ENT endoscopes and reviews a number of technologies including Tristel's Wipes System, Stella decontamination system and Shine automated washer-disinfector. 

 

The second publication is of a study undertaken in the Prince of Wales Hospital, Hong Kong, and is titled "Transvaginal ultrasound probe contamination by the human papillomavirus in the emergency department" (Emergency Medicine Journal, July 2012). The study revealed the prevalence of human papillomavirus (HPV) on the ultrasound equipment used routinely in the hospital and indicated that existing disinfection methods were inappropriate. The hospital has adopted the Tristel Wipes System to improve its decontamination process. 

 

Tristel CEO, Paul Swinney, commented: "We believe the Wipes System is now gaining recognition as the "gold standard" for ENT endoscopes in countries where it has been approved for use, which include all those in the European Community, Australia and many countries in the Far East. Whilst we have not attempted to register the Wipes System in the United States, its inclusion in The Laryngoscope review of decontamination methodologies, which is the most widely read journal for ENT worldwide, is a significant benefit to the marketing of our product.

 

"A second area in the hospital where the Wipes System is achieving rapid uptake in the United Kingdom and Australia is ultrasound. The Prince of Wales study joins a growing body of scientific evidence that existing methods of disinfecting intra-vaginal and rectal ultrasound probes are inadequate. The Wipes System is considered to be a more effective method of disinfection. In terms of patient procedures, and therefore disinfectant use, ultrasound is as large a market as digestive and respiratory medicine where almost all the attention of the infection control market has been focused for the past twenty years. Our product strategy of focusing on the smaller non-lumened instruments used in ENT and ultrasound positions us well for continued growth in this area."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFUFMMFDSEDF
Date   Source Headline
23rd Feb 20224:45 pmRNSInterim dividend confirmation
22nd Feb 202211:30 amRNSDirector/PDMR Shareholding
21st Feb 20224:40 pmRNSSecond Price Monitoring Extn
21st Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSHalf-year Report
17th Feb 20223:00 pmRNSIssue of Equity
1st Feb 20227:00 amRNSConfirmation of Interim Results
13th Dec 20215:13 pmRNSResult of AGM
13th Dec 20217:00 amRNSAGM Statement and notice of results
27th Oct 20217:00 amRNSDirector/PDMR Shareholding
21st Oct 20214:39 pmRNSDirector/PDMR Shareholding
19th Oct 20215:35 pmRNSHolding(s) in Company
18th Oct 20213:50 pmRNSIssue of Equity
18th Oct 202111:59 amRNSDirector/PDMR Shareholding
18th Oct 20217:00 amRNSFinal Results
12th Oct 20215:58 pmRNSHolding(s) in Company
22nd Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSIssue of Equity
10th Aug 20217:00 amRNSIssue of Equity
29th Jul 20216:29 pmRNSTR1: Notification of Major Holdings
21st Jul 20217:00 amRNSTrading update
9th Jul 20211:21 pmRNSIssue of Equity
24th Jun 20217:00 amRNSRegulatory approval for EPA, Canada & South Korea
8th Jun 20217:00 amRNSIssue of Equity
13th May 20213:30 pmRNSIssue of Equity
26th Apr 20213:15 pmRNSDirector/PDMR Shareholding
26th Apr 20212:06 pmRNSSecond Price Monitoring Extn
26th Apr 20212:00 pmRNSPrice Monitoring Extension
26th Apr 202111:05 amRNSSecond Price Monitoring Extn
26th Apr 202111:00 amRNSPrice Monitoring Extension
26th Apr 20217:00 amRNSTrading Update
21st Apr 20213:00 pmRNSIssue of Equity
19th Apr 20211:00 pmRNSIssue of Equity
6th Apr 20211:00 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
26th Mar 202110:40 amRNSIssue of Equity
4th Mar 20217:00 amRNSDirector/PDMR Shareholding
1st Mar 20215:00 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Feb 20217:00 amRNSHalf-year Report
18th Feb 202111:15 amRNSNotice of investor presentation
15th Feb 202111:00 amRNSIssue of Equity
29th Jan 20217:00 amRNSIssue of Equity
14th Jan 20212:00 pmRNSExercise of Options
24th Dec 20207:00 amRNSDirector Appointment
15th Dec 202011:39 amRNSResult of AGM
15th Dec 20207:00 amRNSAGM Statement and notice of results
2nd Dec 20202:00 pmRNSUpdate to Executive Performance Share Plan 2021
2nd Dec 202010:30 amRNSTristel wins AIM Growth Business of the Year Award
9th Nov 20209:49 amRNSExercise of Options
2nd Nov 202010:30 amRNSQ&A update following preliminary results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.